{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:02:10Z","timestamp":1780981330182,"version":"3.54.1"},"reference-count":64,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2004]]},"DOI":"10.5551\/jat.11.313","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T13:45:32Z","timestamp":1308231932000},"page":"313-321","source":"Crossref","is-referenced-by-count":48,"title":["The Roles of Cytokines, Inflammation and Immunity in Vascular Diseases"],"prefix":"10.5551","volume":"11","author":[{"given":"Fumitaka","family":"Ohsuzu","sequence":"first","affiliation":[{"name":"The First Department of Medicine, National Defense Medical College, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"(1) Ridker PM: On evolutionary biology, inflammation, infection, and the cause of atherosclerosis. Circulation, 105: 2−4, 2002","DOI":"10.1161\/circ.105.1.2"},{"key":"2","doi-asserted-by":"crossref","unstructured":"(2) Binder CJ, Chang M-K, Shaw PX, Miller YI, Hartvigsen K, Dewan A, and Witztum JL: Innate and acquired immunity in atherogenesis, Nat Med, 8: 1218−1225, 2002","DOI":"10.1038\/nm1102-1218"},{"key":"3","doi-asserted-by":"crossref","unstructured":"(3) Hasegawa T, Negishi T, and Deguchi M: WBC count, atherosclerosis and coronary risk factors. J Atheroscler Thromb, 9: 219−223, 2002","DOI":"10.5551\/jat.9.219"},{"key":"4","doi-asserted-by":"crossref","unstructured":"(4) Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, and Ohsuzu F: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis, 170: 333−337, 2003","DOI":"10.1016\/S0021-9150(03)00298-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"(5) Fan J and Watanabe T: Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb, 10: 63−71, 2003","DOI":"10.5551\/jat.10.63"},{"key":"6","doi-asserted-by":"crossref","unstructured":"(6) Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, and Nagai R: Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med, 8: 403−409, 2002","DOI":"10.1038\/nm0402-403"},{"key":"7","doi-asserted-by":"crossref","unstructured":"(7) Dinarello CA: Biologic basis for interleukin-1 in disease. Blood, 87: 2095−2147, 1996","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095"},{"key":"8","doi-asserted-by":"crossref","unstructured":"(8) Wang X, Romanic AM, Yue TL, Feuerstein GL, and Ohlstein EH: Expression of interleukin-1beta, interleukin-1 receptor, and interleukin-1 receptor antagonist mRNA in rat carotid artery after balloon angioplasty. Biochem Biophys Res Commun, 271: 138−143, 2000","DOI":"10.1006\/bbrc.2000.2588"},{"key":"9","doi-asserted-by":"crossref","unstructured":"(9) Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, and Ozaki CK: Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation, 102: 1697−1702, 2000","DOI":"10.1161\/01.CIR.102.14.1697"},{"key":"10","doi-asserted-by":"crossref","unstructured":"(10) Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, and Seishima M: Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol, 23: 656−660, 2003","DOI":"10.1161\/01.ATV.0000064374.15232.C3"},{"key":"11","unstructured":"(11) Loppnow H, Werdan K, Reuter G, and Flad HD: The interleukin-1 and interleukin-1 converting enzyme families in the cardiovascular system. Eur Cytokine Netw, 9: 675−680, 1998"},{"key":"12","doi-asserted-by":"crossref","unstructured":"(12) Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, and Ohsuzu F: Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation, 108: 516−518, 2003","DOI":"10.1161\/01.CIR.0000085567.18648.21"},{"key":"13","doi-asserted-by":"crossref","unstructured":"(13) Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, and Ohsuzu F: Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 24: 1068−1073, 2004","DOI":"10.1161\/01.ATV.0000127025.48140.a3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"(14) Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, and Tedgui A: Interleukin-18\/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res, 89: e41−e45, 2001","DOI":"10.1161\/hh1901.098735"},{"key":"15","doi-asserted-by":"crossref","unstructured":"(15) Whitman SC, Ravisankar P, and Daugherty A: Interleukin-18 enhances atherosclerosis in Apolipoprotein E-\/-<\/SUP> mice through release of interferon-γ, Circ Res, 90: e34−e38, 2002","DOI":"10.1161\/hh0202.105292"},{"key":"16","doi-asserted-by":"crossref","unstructured":"(16) Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, and Hirokawa K: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest, 92: 2814−2820, 1993","DOI":"10.1172\/JCI116901"},{"key":"17","doi-asserted-by":"crossref","unstructured":"(17) Giachelli CM, Base N, Almeida MM, Denhardt DT, Alpers CE, and Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest, 92: 1686−1696, 1993","DOI":"10.1172\/JCI116755"},{"key":"18","doi-asserted-by":"crossref","unstructured":"(18) Giachelli C, Bae N, Lombardi D, Majesky M, and Schwartz S: Molecular cloning and characterization of 2B7, a rat mRNA which distinguishes smooth muscle cell phenotypes in vitro and is identical to osteopontin (secreted phosphoprotein I, 2aR). Biochem Biophys Res Commun, 177: 867−873, 1991","DOI":"10.1016\/0006-291X(91)91870-I"},{"key":"19","doi-asserted-by":"crossref","unstructured":"(19) Gadeau AP, Campan M, Millet D, Candresse T, and Desgranges C: Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb, 13: 120−125, 1993","DOI":"10.1161\/01.ATV.13.1.120"},{"key":"20","doi-asserted-by":"crossref","unstructured":"(20) Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, and Ohsuzu F: Osteopontine plays an important role in the development of medial thickening and neointimal formation. Circ Res, 91: 77−82, 2002","DOI":"10.1161\/01.RES.0000025268.10302.0C"},{"key":"21","doi-asserted-by":"crossref","unstructured":"(21) Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, and Ohsuzu F: Osteopontin transgenic mice fed a high-cholesterol diet develop fatty-streak lesions. Circulation, 107: 679−681, 2003","DOI":"10.1161\/01.CIR.0000055739.13639.D7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"(22) Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, and Cantor H: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science, 287: 860−864, 2000","DOI":"10.1126\/science.287.5454.860"},{"key":"23","doi-asserted-by":"crossref","unstructured":"(23) Mallat Z, Besnard S, Duriez M, Deleuze V, Emanuel F, Dureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, and Tedgui A: Protective role of interleukin-10 in atherosclerosis. Circ Res, 85: e17−e24, 1999","DOI":"10.1161\/01.RES.85.8.e17"},{"key":"24","doi-asserted-by":"crossref","unstructured":"(24) Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA, and Fyfe AI: Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Atheroscler Thomb Vasc Biol, 19: 2847−2853, 1999","DOI":"10.1161\/01.ATV.19.12.2847"},{"key":"25","doi-asserted-by":"crossref","unstructured":"(25) Zhou X, Paulsson G, Stemme S, and Hansson GK: Hypercholesterolemia is associated with a T helper (Th) 1\/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101: 1717−1725, 1998","DOI":"10.1172\/JCI1216"},{"key":"26","doi-asserted-by":"crossref","unstructured":"(26) Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, and Hansson GK: Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145: 33−43, 1999","DOI":"10.1016\/S0021-9150(99)00011-8"},{"key":"27","doi-asserted-by":"crossref","unstructured":"(27) Latz E, and Golenbock DT: Receptor "cross talk" in innate immunity. J Clin Invest, 112: 1136−1137, 2003","DOI":"10.1172\/JCI200320040"},{"key":"28","doi-asserted-by":"crossref","unstructured":"(28) Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu ZG, and Su B: Differential regulation of interleukin 1 receptor and toll-like receptor signaling by MEKK3. Nat Immunol, 5: 98−103, 2004","DOI":"10.1038\/ni1014"},{"key":"29","doi-asserted-by":"crossref","unstructured":"(29) Fan J, Frey RS, and Malik AB: TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest, 112: 1234−1243, 2003","DOI":"10.1172\/JCI18696"},{"key":"30","doi-asserted-by":"crossref","unstructured":"(30) Matsuguchi T, Musikacharoen T, Ogawa T, and Yasunobu Y: Gene expression of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol, 165: 5767−5772, 2000","DOI":"10.4049\/jimmunol.165.10.5767"},{"key":"31","doi-asserted-by":"crossref","unstructured":"(31) Mocellin S, Panelli MC, Wang E, Nagorsen D, and Marincola M: The dual role of IL-10, Trends Immunol, 24: 36−43, 2003","DOI":"10.1016\/S1471-4906(02)00009-1"},{"key":"32","doi-asserted-by":"crossref","unstructured":"(32) Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med, 340: 115−126, 1999","DOI":"10.1056\/NEJM199901143400207"},{"key":"33","doi-asserted-by":"crossref","unstructured":"(33) Shah PK: Circulatory markers of inflammation for vascular risk prediction; are they ready for prime time. Circulation, 105: 1758−1759, 2000","DOI":"10.1161\/01.CIR.101.15.1758"},{"key":"34","doi-asserted-by":"crossref","unstructured":"(34) Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, and Freeman MW: Reduced atherosclerosis in Myd88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med, 10: 416−421, 2004","DOI":"10.1038\/nm1008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"(35) Libby P, Ridker PM, and Maseri A: Inflammation and atherosclerosis. Circulation, 105: 1135−1143, 2002","DOI":"10.1161\/hc0902.104353"},{"key":"36","doi-asserted-by":"crossref","unstructured":"(36) Paul A, Ko K W, Li L, Yechoor V, McCrory MA, Szalai AJ, and Chan L: C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation, 109: 647−655, 2004","DOI":"10.1161\/01.CIR.0000114526.50618.24"},{"key":"37","doi-asserted-by":"crossref","unstructured":"(37) Patti G, D’Ambrosio A, Mega S, Giorgi G, Zardi EM, Zardi DM, Dicuonzo G, Dobrina A, and Sciascio GD: Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol, 43: 35−38, 2004","DOI":"10.1016\/j.jacc.2003.07.032"},{"key":"38","doi-asserted-by":"crossref","unstructured":"(38) Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, and Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation, 104: 1598−1603, 2001","DOI":"10.1161\/hc3901.096721"},{"key":"39","doi-asserted-by":"crossref","unstructured":"(39) Heeschen C, Dimmeler S, Hamm CW, Frichtlscherer S, Boersma E, Simooons ML, Zeiher AM and for the CAPTURE Study Investigators: Serum level of the anti-inflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation, 107: 2109−2114, 2003","DOI":"10.1161\/01.CIR.0000065232.57371.25"},{"key":"40","doi-asserted-by":"crossref","unstructured":"(40) El-Omar EM, Carrington M, Chow W-H, McColl KEL, Bream JH, Young HA, Herrera J, Lissowska J, Yuan C-C, Rothman N, Lanyon G, Martin M, Fraumeni JFJr, and Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404: 398−402, 2000","DOI":"10.1038\/35006081"},{"key":"41","doi-asserted-by":"crossref","unstructured":"(41) Mayr M, Kiechl S, Willeit J, Wick G and Xu Q: Infection, immunity and atherosclerosis. Associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori and Cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation, 102: 833−839, 2000","DOI":"10.1161\/01.CIR.102.8.833"},{"key":"42","doi-asserted-by":"crossref","unstructured":"(42) Momiyama Y, Hirano R, Taniguchi H, Nakamura H, and Ohsuzu F: Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection. J Am Coll Cardiol, 38: 712−717, 2001","DOI":"10.1016\/S0735-1097(01)01438-3"},{"key":"43","doi-asserted-by":"crossref","unstructured":"(43) Danis VA, Millington M, Hyland VJ, and Grennan D: Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1 Ra) gene polymorphism. Clin Exp Immunol, 99: 303−310, 1995","DOI":"10.1111\/j.1365-2249.1995.tb05549.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"(44) Mansfield JC, Holden H, Tarlow JK, Di Giovine FS, McDowell TL, Wilson AG, Holdsworth CD, and Duff GW: Novel genetic association between ulcerative colitis and anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology, 106: 637−642, 1994","DOI":"10.1016\/0016-5085(94)90696-3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"(45) Blakemore AIF, Cox A, Gonzalez AM, Maskill JK, Hughes ME, Wilson RM, Ward JD, and Duff GW: Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet, 97: 369−374, 1996","DOI":"10.1007\/s004390050055"},{"key":"46","doi-asserted-by":"crossref","unstructured":"(46) Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG, and Duff GW: An allele of interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata, J Invest Dermatol, 104: 15S−16S, 1995","DOI":"10.1038\/jid.1995.37"},{"key":"47","doi-asserted-by":"crossref","unstructured":"(47) Edfeldt K, Swedenborg J, Hansson GK, and Yan ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation, 105: 1158−1161, 2002","DOI":"10.1161\/circ.105.10.1158"},{"key":"48","doi-asserted-by":"crossref","unstructured":"(48) Xu XH, Shap PK, Faure E, Equlis O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, and Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation, 104: 3103−3108, 2001","DOI":"10.1161\/hc5001.100631"},{"key":"49","doi-asserted-by":"crossref","unstructured":"(49) Faure E, Thomas L, Xu H, Medvedev A, Equils O, and Arditi M: Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol, 166: 2018−2024, 2001","DOI":"10.4049\/jimmunol.166.3.2018"},{"key":"50","doi-asserted-by":"crossref","unstructured":"(50) Visintin A, Mazzoni A, Spitzer JA, Wyllie DH, Dower SK, and Segal DM: Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol, 166: 249−255, 2001","DOI":"10.4049\/jimmunol.166.1.249"},{"key":"51","doi-asserted-by":"crossref","unstructured":"(51) Ashida K, Miyazaki K, Takayama E, Tsujimoto H, Ayaori M, Yakushiji T, Iwamoto N, Yonemura A, Isoda K, Mochizuki H, Hiraide H, Kusuhara M, and Ohsuzu F: Characterization of the expression of TLR2 (Toll-like receptor 2) and TLR4 on circulating monocytes in coronary artery disease. J Atheroscler Thromb, 12, 2005 (in press)","DOI":"10.5551\/jat.12.53"},{"key":"52","doi-asserted-by":"crossref","unstructured":"(52) Kluft C, and De Maat MP: Genetics of c-reactive protein. New possibilities and complications. Atheroscler Thromb Vasc Biol, 23: 1956−1959, 2003","DOI":"10.1161\/01.ATV.0000100113.47260.EB"},{"key":"53","doi-asserted-by":"crossref","unstructured":"(53) Nagatomi A, Freeman SB, Geczy CL: Interferon-É¡ and its lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein. Relationship with age, sex, and hormone replacement treatment. Circulation, 101: 1785−1791, 2000","DOI":"10.1161\/01.CIR.101.15.1785"},{"key":"54","doi-asserted-by":"crossref","unstructured":"(54) Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet, 350: 430−436, 1997","DOI":"10.1016\/S0140-6736(97)03079-1"},{"key":"55","doi-asserted-by":"crossref","unstructured":"(55) Mach F: Statins as immunomodulators. Transpl Immunol, 9: 197−200, 2002","DOI":"10.1016\/S0966-3274(02)00030-8"},{"key":"56","doi-asserted-by":"crossref","unstructured":"(56) Mach F: Statins as immunomodulatory agents. Circulation, 109 suppl II: II15−II17, 2004","DOI":"10.1161\/01.CIR.0000129502.10459.fe"},{"key":"57","doi-asserted-by":"crossref","unstructured":"(57) Yoshida M: Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb, 10: 140−144, 2003","DOI":"10.5551\/jat.10.140"},{"key":"58","doi-asserted-by":"crossref","unstructured":"(58) Van Doornum S, McColl G, and Wicks IP: Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum, 46: 862−873, 2002","DOI":"10.1002\/art.10089"},{"key":"59","doi-asserted-by":"crossref","unstructured":"(59) del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum, 44: 2737−2745, 2001","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"60","doi-asserted-by":"crossref","unstructured":"(60) Sattar N, McCarey DW, Capell H, and McInnes IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation, 108: 2957−2963, 2003","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"61","doi-asserted-by":"crossref","unstructured":"(61) Palinski W and Napoli C: Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol, 22: 1745−1750, 2002","DOI":"10.1161\/01.ATV.0000038754.39483.CD"},{"key":"62","doi-asserted-by":"crossref","unstructured":"(62) Youssef F, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, and Steinman L: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 420: 78−84, 2002","DOI":"10.1038\/nature01158"},{"key":"63","doi-asserted-by":"crossref","unstructured":"(63) Uyemura K, Demer LL, Castle SCÅAJullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, and Modlin RL: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest, 97: 2130−2138, 1996","DOI":"10.1172\/JCI118650"},{"key":"64","doi-asserted-by":"crossref","unstructured":"(64) Schönbeck U, and Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors. Statins as anti-inflammatory agents?, Circulation, 109 suppl II: II18−II26, 2004","DOI":"10.1161\/01.CIR.0000129505.34151.23"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/11\/6\/11_6_313\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T05:25:37Z","timestamp":1592630737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/11\/6\/11_6_313\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.11.313","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}